登录 注册 会员服务 联系我们

Nusinersen for Spinal Muscular Atrophy

  • Published:2018-02-01 Issue:2 Volume:172 Page:123
  • ISSN:2168-6203
  • Container-title:JAMA Pediatrics
  • language:en
  • Short-container-title:JAMA Pediatr

Author:

Prasad Vinay123

Affiliation:

1. Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland

2. Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland

3. Center for Health Care Ethics, Oregon Health & Science University, Portland

Publisher

American Medical Association (AMA)

Subject

Pediatrics, Perinatology, and Child Health

Reference13 articles.

1. Five years of cancer drug approvals: innovation, efficacy, and costs.;Mailankody;JAMA Oncol,2015

2. Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy;Burgart;JAMA Pediatr

3. Clinical trials: new drug for pancreatic cancer highlights the dual effect of regulatory approvals.;Bates;Nat Rev Clin Oncol,2016

4. Randomized versus historical controls for clinical trials.;Sacks;Am J Med,1982

5. The high price of anticancer drugs: origins, implications, barriers, solutions.;Prasad;Nat Rev Clin Oncol,2017
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3